Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

[1]  Matthias Herz,et al.  Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study , 2014, BMC Nephrology.

[2]  Joseph G Ibrahim,et al.  Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes , 2012, Biometrics.

[3]  Samy Suissa,et al.  The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study , 2012, BMJ : British Medical Journal.

[4]  Natalie L. Catlett,et al.  Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes , 2012, PloS one.

[5]  T. Craven,et al.  Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants , 2012, Diabetes Care.

[6]  Armin Ruf,et al.  Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors , 2012, ChemMedChem.

[7]  T. Johnson,et al.  Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial , 2012, BMJ : British Medical Journal.

[8]  N. Perico,et al.  Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. , 2011, International journal of cardiology.

[9]  W. Bilker,et al.  Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.

[10]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[11]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[12]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[13]  S. Mudaliar,et al.  Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.

[14]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[15]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[16]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[17]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[18]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[19]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007 .

[20]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[21]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[22]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[23]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[24]  E. Braunwald,et al.  Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .

[25]  Judith Wylie-Rosett,et al.  Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.

[26]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[27]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[28]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[29]  B. Staels,et al.  Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.

[30]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[31]  Shankar Subramaniam,et al.  Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes , 2004, Bioinform..

[32]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[33]  Irene M. Stratton,et al.  UK prospective diabetes study (UKPDS) , 2004, Diabetologia.

[34]  N. Wareham,et al.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.

[35]  任艳,et al.  胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .

[36]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[37]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[38]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[39]  R. Holman,et al.  U.K. Prospective Diabetes Study , 1996, Diabetes Care.

[40]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.